ITCI | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 4%

Liquidity 75%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0.52%

2 Year

97.94%

Key data

Stock price

$131.87

P/E Ratio

0.00

DAY RANGE

$131.63 - $131.98

EPS

-$0.72

52 WEEK RANGE

$131.19 - $131.98

52 WEEK CHANGE

$0.47

MARKET CAP

8.855 B

YIELD

N/A

SHARES OUTSTANDING

105.667 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-11-2025

BETA

0.83

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Sharon Mates
Region: US
Website: intracellulartherapies.com
Employees: 560
IPO year: 2013

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Intra-Cellular Therapies, Inc. develops novel drugs for the treatment of neuropsychiatric and neurologic diseases. The company offers CAPLYTA for schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for bipolar depression, as well as to treat autism spectrum disorder.

ITCI - Intra-Cellular Therapies, Inc.